Our Focus
Developing research-driven approaches to address unmet public health challenges.
We are committed to
Providing Therapeutic Solutions that heal and improve patient outcomes.
2
2
Patents Filled
Patents Filled
10+
10+
Partnerships
Partnerships
500+
500+
Established Network Professionals
Network Professionals
We Bridge The Gap
We Bridge The Gap
Sanare Bioscience conducts early-stage research in lipid-based science, toxicology, cannabinoid-related exposures, and neurological and behavioral impacts. We collaborate with scientific and community partners to support foundational research where significant knowledge gaps remain.
Our efforts focus on generating research insights that can inform future development and public-health preparedness in emerging cannabinoid challenges.
Sanare Bioscience conducts early-stage research in lipid-based science, toxicology, cannabinoid-related exposures, and neurological and behavioral impacts. We collaborate with scientific and community partners to support foundational research where significant knowledge gaps remain.
Our efforts focus on generating research insights that can inform future development and public-health preparedness in emerging cannabinoid challenges.
Our Expertise
Lipid-Based Molecules
Drug Repurposing
Toxicity
Brain Health
Advancing Research in Critical Areas
Lipid-Based Molecules
Toxicity
Drug Repurposing
Brain Health
Lipid-Based Molecules
Exploring lipid-based technologies for potential scientific application across toxicology and emergency research.
Drug Repurposing
Investigating unmet needs and supporting research into cannabis-related emergencies affecting diverse populations.
Toxicity
Studying pathways and exposure mechanisms related to emerging drugs and environmental toxicants.
Brain Health
Supporting early-stage research into neurological and behavioral aspects related to substance exposure.
*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173933/
** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
*https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173933/
** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/
Flagship Focus
Acute Cannabinoid Intoxication (ACI) and
Cannabinoid Hyperemesis Syndrome (CHS)
Cannabis intoxication and CHS cases continue to rise, yet no FDA-approved treatment exists today. Sanare Bioscience supports early-stage scientific investigation into lipid-based mechanisms that may help inform future pathways in cannabinoid toxicity research.
Cannabis intoxication and CHS cases continue to rise, yet no FDA-approved treatment exists today. Sanare Bioscience supports early-stage scientific investigation into lipid-based mechanisms that may help inform future pathways in cannabinoid toxicity research.
*Cannabis Consumer Report by Drive Research
CHS Patient Lifetime Financial Burden
CHS Patient Lifetime Financial Burden
CHS Patient Lifetime
Financial Burden
Due to repeated hospital visits, extensive tests, and unnecessary procedures.
Due to repeated hospital visits, extensive tests, and unnecessary procedures.
Annual Cost to Hospitals per CHS Patient
Annual Cost to Hospitals per CHS Patient
CHS Patient Lifetime
Financial Burden
Strains hospital resources, diverts attention from other critical cases, and ultimately impacts overall healthcare quality.
Strains hospital resources, diverts attention from other critical cases, and ultimately impacts overall healthcare quality.
Flagship Focus
Market
With cannabis access expanding across North America, accidental exposures, emergency department visits, and cannabinoid-related complications continue to rise. This drives an urgent need for increased research, awareness, and collaboration in public health and toxicology.
ACI and CHS cases are expected to increase with legalization, emphasizing the urgent need for an approved treatment.
With cannabis access expanding across North America, accidental exposures, emergency department visits, and cannabinoid-related complications continue to rise. This drives an urgent need for increased research, awareness, and collaboration in public health and toxicology.
ACI and CHS cases are expected to increase with legalization, emphasizing the urgent need for an approved treatment.
Partner with Sanare
We welcome collaboration with researchers, healthcare systems, advocacy groups, and public health leaders dedicated to advancing responsible scientific development.
Flagship Focus
Market
The Drug Enforcement Administration (DEA) recently announced their decision to deschedule cannabis, removing it from the list of controlled substances under the Controlled Substances Act (CSA).
As of 2023, 24 states have legalized cannabis and this number is expected to grow as more states consider their own marijuana policies in light of this federal development decision.
ACI and CHS cases are expected to increase with legalization, emphasizing the urgent need for an approved treatment.